Evidence map›Paper›PMID 34270395›Full record

ArticleHuman vaccines & immunotherapeutics2021

Tumor targeting nanoparticle E7

Yue Zhang, Faliang Ren, Bing Ni, Tao Jing, Jun Tang

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Nanovaccines empowering CD8Theranostics · 2025
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yue ZhangDepartment of Dermatology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Faliang RenDepartment of Dermatology, Children's Hospital of Chongqing Medical University, Chongqing, China.
Bing NiDepartment of Pathophysiology, Third Military Medical University, Chongqing, China.
Tao JingDepartment of Cardiology, Southwest Hospital, Third Military Medical University, Chongqing, China.
Jun TangDepartment of Dermatology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
University of Science and Technology of China · CNArmy Medical University · CNChongqing Medical University · CNSouthwest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous research verified that HSP (heat shock protein) 110 could enhance the anti-tumor effect of HPV16 E7

Indexed as

Cancer VaccinesNanoparticlesUterine Cervical NeoplasmsAnimalsCD8-Positive T-LymphocytesFemaleHumansImmunityMiceMice, Inbred C57BLOligopeptidesPapillomavirus E7 ProteinsCancer VaccinesOligopeptidesPapillomavirus E7 Proteinscervical cancerHPV16 E7HSP110nanoparticle vaccineRGD

Identifiers

PMID34270395
PMCPMC8437488
OpenAlexW3178371683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.